Daily Anesthesiology Research Analysis
Analyzed 87 papers and selected 3 impactful papers.
Summary
Three anesthesiology-relevant studies stand out today: a comprehensive meta-analysis finds no increased acute kidney injury risk from modern hydroxyethyl starch in surgical patients; a randomized trial shows preoperative 5 mg olanzapine improves Quality of Recovery and reduces postdischarge nausea; and a Lancet Respiratory Medicine cohort reveals that hypoinflammatory ARDS shows stronger mortality associations with driving pressures, informing phenotype-guided trial design.
Research Themes
- Perioperative fluid therapy safety and renal outcomes
- Postoperative recovery optimization and PONV prevention
- Phenotype-informed ventilation strategies in critical care
Selected Articles
1. Hydroxyethyl Starch and Perioperative Complications: a Systematic Review and Meta-analysis.
Pooling 114 trials (13,951 patients), modern HES (130/0.4 or 130/0.42) did not increase acute kidney injury (RR 1.02 [0.91–1.16]) nor worsen perioperative creatinine change. Trial sequential analysis supported non-inferiority for creatinine change, and no meaningful increases were seen in adverse events or mortality. Most trials limited HES to <24 hours.
Impact: This meta-analysis directly addresses regulatory concerns about HES in surgical patients and provides contemporary evidence refuting increased renal risk, potentially reshaping perioperative fluid policies.
Clinical Implications: In surgical patients without critical illness, modern HES solutions (130/0.4–0.42) used for <24 hours appear renal-safe, supporting their selective use within goal-directed fluid therapy while continuing to avoid use in sepsis/critical illness per existing evidence.
Key Findings
- Across 114 trials (13,951 patients), HES 130/0.4–0.42 did not increase AKI risk (RR 1.02 [0.91, 1.16]).
- Perioperative creatinine change was non-inferior with HES (mean difference −0.62 [−3.82, 2.57] µmol/L).
- No meaningful worsening of adverse events or mortality; nearly all trials limited HES to <24 h.
Methodological Strengths
- Extensive dataset including 114 trials with low risk of bias and no publication bias detected
- Trial sequential analysis supporting adequacy of information size and non-inferiority for creatinine change
Limitations
- Heterogeneity in surgical populations and fluid comparators; renal outcomes largely short-term
- Most trials restricted HES to <24 h, limiting extrapolation to prolonged use
Future Directions: Pragmatic, registry-embedded RCTs in contemporary ERAS pathways should compare HES versus crystalloids/albumin in defined subgroups (e.g., cardiac, baseline CKD), with standardized AKI definitions and long-term renal follow-up.
BACKGROUND: Based on renal injury reported in critically ill and septic patients, the Food and Drug Administration issued a black box warning regarding hydroxyethyl starch (HES 130/0.4) use in 2013, and expanded the warning to surgical and trauma patients in 2021. Similarly, the European Medicines Agency initiated withdrawal of hydroxyethyl starch in 2022. We therefore conducted a new meta-analysis focused on renal injury designed to complement a 2021 meta-analysis of perioperative hydroxyethyl starch use, add
2. Preoperative Olanzapine and Quality of Recovery after Ambulatory Surgery: A Randomized Clinical Trial.
In 384 ambulatory female patients, preoperative olanzapine 5 mg improved QoR-40 on POD 1 by 9.0 points and on POD 2 by 4.8 points versus placebo, and reduced odds of any and severe nausea on POD 1 without prolonging PACU stay. Benefits persisted after multiple-comparison correction.
Impact: A rigorously conducted, registered randomized trial demonstrates that a low-dose antipsychotic enhances patient-centered recovery outcomes in addition to reducing PDNV, informing multimodal antiemetic and recovery strategies.
Clinical Implications: Consider adding 5 mg olanzapine preoperatively to dexamethasone and ondansetron in ambulatory women at PDNV risk, with counseling on possible sedation and tailored patient selection beyond the studied population.
Key Findings
- QoR-40 improved on POD 1 by 9.0 points (95% CI 6.1–11.8; p<0.001) and on POD 2 by 4.8 points (95% CI 2.0–7.6).
- Lower odds of any nausea on POD 1 (OR 0.43; 95% CI 0.28–0.66) and severe nausea (OR 0.26; 95% CI 0.14–0.48).
- PACU length of stay was similar between groups; results held after FDR correction.
Methodological Strengths
- Randomized, double-blind, placebo-controlled design with prospective registration (NCT05676294)
- Mixed-effects analysis adjusted for baseline QoR-40; multiplicity controlled via FDR
Limitations
- Single-center study limited to 18–50-year-old females; generalizability to other populations is uncertain
- Sedation-related outcomes beyond PACU length of stay were not deeply characterized
Future Directions: Multicenter trials across sexes, ages, and procedures should compare doses (e.g., 2.5–10 mg), assess sedation/cognitive effects, and integrate patient-reported recovery metrics over longer horizons.
BACKGROUND: Postdischarge nausea and vomiting (PDNV) negatively impact recovery after surgery. Preoperative administration of olanzapine 10 mg decreases PDNV but increases sedation. No data are available on the impact of olanzapine on global quality of recovery. METHODS: This was a single-center, randomized, double-blind, placebo-controlled trial in 18-50-year-old female patients undergoing ambulatory surgery under general anesthesia. Participants received oral olanzapine 5 mg or placebo in additio
3. Effects of inflammatory phenotypes in acute respiratory distress syndrome on mortality and partitioning of lung and chest wall mechanics in patients in the USA and Canada: a retrospective cohort study.
Among 890 moderate-to-severe ARDS patients, 48% were hyperinflammatory (60-day mortality 55%) and 52% hypoinflammatory (29%). High respiratory system and transpulmonary driving pressures were more strongly associated with 60-day mortality in hypoinflammatory ARDS, suggesting phenotype-specific risk gradients but not distinct ventilation targets.
Impact: This large, phenotype-stratified analysis links lung-protective mechanics to outcomes differently across ARDS phenotypes, guiding enrichment strategies for future ventilation trials and precision critical care.
Clinical Implications: Maintain strict lung-protective ventilation for all ARDS, with recognition that hypoinflammatory phenotypes may be particularly sensitive to driving pressures. Use phenotype stratification to design and power future interventional trials.
Key Findings
- In 890 ARDS patients, hyperinflammatory phenotype had 60-day mortality 55% vs 29% in hypoinflammatory phenotype.
- High driving pressure and transpulmonary driving pressure had stronger mortality associations in hypoinflammatory ARDS.
- Findings support trial enrichment by inflammatory phenotype rather than changing ventilation targets by phenotype.
Methodological Strengths
- Harmonised data from a randomized trial (EPVent-2) and a large tertiary cohort with oesophageal manometry
- Multivariable Cox models evaluating respiratory mechanics and phenotype-specific associations
Limitations
- Retrospective analysis subject to residual confounding and selection biases
- Phenotype assignment and generalizability beyond included centers may be limited
Future Directions: Prospective trials stratified by inflammatory phenotype should test differential effects of driving pressure/PEEP strategies and evaluate organ failure trajectories.
BACKGROUND: Inflammatory phenotypes of acute respiratory distress syndrome (ARDS) predict outcomes and can respond differently to treatment strategies. We aimed to establish whether these phenotypes differ in respiratory mechanics and in response to lung-protective ventilation strategies. METHODS: In this retrospective cohort study, data from two cohorts were harmonised. Patients with moderate-to-severe ARDS with oesophageal manometry data from the EPVent-2 trial (14 hospitals across the USA and Canada)